RapidAI’s Rapid Hyperdensity tool reportedly allows quicker assessment of hyperdense tissue in the brain via non-contrast computed tomography (CT) scans.
RapidAI has received FDA 510(k) clearance for Rapid Hyperdensity, an artificial intelligence (AI)-enabled tool that may allow for more timely assessment of traumatic brain injuries and hemorrhages.
Rapid Hyperdensity’s AI-powered review of non-contrast computed tomography (CT) enables radiologists to quickly determine the extent of hyperdense tissue volume associated with acute neurological conditions such as intracerebral hemorrhage (ICH), according to RapidAI.
Alejandro M. Spiotta, M.D., said the automated detection of intracranial hyperdense tissue volume with Rapid Hyperdensity is a significant advance in facilitating timely triage and ongoing assessment of patients with ICH.
“Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient,” noted Dr. Spiotta, the director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention.”
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.